OcyonBio Partner Biosimilar Solutions Reports the Initiation of Registrational Clinical Trials for Biosimilar BSC1020 to Treat Cancer
Shots:
- The company initiates the registrational clinical trials to evaluate the biosimilarity of BSC1020 vs Neupogen in patients with cancer. The trial is expected to complete in July 2022
- Neupogen has been manufactured at Amgen's Biologics facility in Puerto Rico while the trial is designed to identify the similarity b/w biosimilar and Neupogen
- The company has entered into a manufacturing and operations agreement with OcyonBio & has plans to complete a technology transfer to initiate manufacturing in Puerto Rico in 2022. The company will use its multiple assets for the research, development, and manufacture of biosimilar therapies
Ref: Globe Newswire | Image: OcyonBio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
